Phase I Trial of Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Big Ten Cancer Research Consortium BTCRC-AML18-342
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Nivolumab (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
Most Recent Events
- 09 Oct 2020 Planned End Date changed from 1 Oct 2022 to 28 Sep 2020.
- 09 Oct 2020 Planned primary completion date changed from 1 Oct 2021 to 28 Sep 2020.
- 09 Oct 2020 Status changed from recruiting to withdrawn prior to enrolment.